The Centers for Medicare & Medicaid Services (CMS) has announced that 33 states, along with the District of Columbia and…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Acute chest syndrome (ACS), a form of lung injury associated with sickle cell disease (SCD), is driven by…
The U.S. Food and Drug Administration has granted orphan drug status to Sanofi’s rilzabrutinib, an investigational therapy aimed at…
Women with sickle cell disease (SCD) have markedly elevated levels of C-reactive protein (CRP), a marker of body-wide inflammation,…
Researchers have developed a modelling system of tiny blood vessels to track inflammation-driven blood clot formation that can cause complications…
Sickle cell disease (SCD) is associated with enhanced immune B-cell responses and the production of self-reactive antibodies that target…
The first patient has been enrolled in a Phase 1 clinical trial evaluating the safety and tolerability of Rigel…
Immvention Therapeutix has partnered with Novo Nordisk to develop oral treatments for people with sickle cell disease…
Cognitive behavioral therapy (CBT) and pain education, each delivered using digital mobile systems and supported by a peer health coach,…
Adding cyclosporin H to a new lentivirus-delivered gene therapy with enhanced anti-sickling properties boosted the uptake of genetic material in…